The appointments reflect the increasingly integrated nature of modern oncology research, in which laboratory discoveries, clinical trial design, pharmacy operations, patient safety, data management, and professional development must function as a single system. NRG Oncology is part of the National Cancer Institute’s National Clinical Trials Network and coordinates multicenter studies across more than 1,300 research sites worldwide, with a major focus on breast, gynecologic, prostate, and other localized or locally advanced cancers.

Rebecca Arend, MD, MPH, has been appointed Gynecology Oncologist Vice Chair of the NRG Translational Science Committee. A gynecologic oncologist, surgeon-scientist, and clinical trial leader, Arend studies how molecular features of cancer can be converted into more precise methods of screening, prognosis, and treatment selection. Her work includes DNA, RNA, protein, and circulating tumor DNA, or ctDNA, a form of genetic material released by tumors into the bloodstream that can provide a minimally invasive view of cancer biology.

Arend’s research is especially focused on ovarian, endometrial, cervical, and other gynecologic cancers, diseases in which tumors can vary substantially at the molecular level even when they arise in the same organ. Biomarker-driven treatment aims to identify those differences and match patients with therapies most likely to work. As Associate Director of Clinical Research at the O’Neal Comprehensive Cancer Center, Arend oversees trial infrastructure, protocol development, workforce training, and the integration of translational research into clinical programs. Within NRG, she is Translational Science Chair of the Ovarian Subcommittee under the Gynecologic Cancer Committee and is involved in developing early-career oncology investigators.

Robin Lockhorst, PharmD, BCOP, BCPS, has been appointed Chair of the NRG Pharmacy Subcommittee. With more than 15 years of experience at Avera Cancer Institute, Lockhorst has worked across oncology pharmacy, bone marrow transplantation, solid organ transplantation, hepatology, and clinical research. She currently serves as Director of Clinical Research, Oncology, where she is expanding satellite research programs and helping build early-phase trial capabilities across the Great Plains region.

Pharmacy leadership is central to the safe delivery of experimental cancer treatments. Clinical pharmacists review protocols, manage investigational drug services, verify dosing and drug interactions, and help ensure that treatment is administered according to highly specific study requirements. Lockhorst has led operational improvements in these areas while supporting protocol review and multidisciplinary education. Her work has also included mentoring pharmacy trainees and helping advance South Dakota’s drug donation and repository pilot program, an initiative designed to improve access to eligible medications.

David Miyamoto, MD, PhD, has been appointed Radiation Oncology Vice Chair of the NRG Translational Science Committee. A radiation oncologist and physician-scientist at Massachusetts General Hospital, an Associate Professor at Harvard Medical School, and an Associate Member of the Broad Institute of MIT and Harvard, Miyamoto investigates how molecular testing and advanced imaging can make cancer treatment more predictive. His laboratory research has emphasized liquid biopsies, tumor genomic analysis, and imaging technologies for prostate and bladder cancers.

The goal of this work is to identify biological signals that reveal whether a tumor is responding to treatment, developing resistance, or progressing before those changes become obvious through conventional clinical assessments. Miyamoto has led NIH-funded research involving liquid biopsy and prostate-specific membrane antigen, or PSMA, positron emission tomography imaging in patients receiving Lu-PSMA-617 radioligand therapy. This treatment delivers radiation to cancer cells that express PSMA, and biomarkers may help determine which patients are most likely to benefit. Miyamoto has also served in translational leadership roles on major multicenter studies, including NRG-GU015, ECOG-ACRIN-NRG 8185, and the PARTIQoL trial.

Elena Nelson, MBA, CCRC, has been appointed Vice Chair of the Clinical Research Associate Subcommittee within the NRG Protocol Support Committee. Nelson brings more than 15 years of oncology research experience from the University of Florida Health Cancer Center, where she serves as Data Management and Academic Research Consortium Network Manager. In that role, she leads data operations for approximately 150 trials involving solid tumors, hematologic malignancies, pediatric cancers, and early-phase therapies.

High-quality data are essential to determining whether a treatment is safe and effective. Nelson has developed standardized workflows to improve the accuracy, completeness, and timeliness of trial information, including data submitted for NCI-sponsored and experimental therapeutics studies. She is also a RECIST subject matter expert. RECIST, or Response Evaluation Criteria in Solid Tumors, is a standardized system used to measure whether tumors have shrunk, remained stable, or grown during treatment. Nelson has worked with NRG on the RECIST CLASS project and has served as both a member and mentor within the Protocol Support Committee.

Cortney Montgomery, MD, MHSc, has been appointed Vice Chair of the NRG Protocol Support Committee Mentorship Subcommittee. With more than 25 years of experience in oncology research nursing and clinical trial coordination, Montgomery has worked in academic medical centers, comprehensive cancer centers, and direct patient-care settings. At UPMC Hillman Cancer Center, she serves as a Clinical Research Coordinator and Treatment Nurse, managing patient screening, informed consent, investigational drug administration, chemotherapy delivery, and protocol compliance while helping establish a new Clinical Translational Research Center.

Montgomery has coordinated Phase I through Phase IV studies, including industry-sponsored, cooperative group, and investigator-initiated trials. Her clinical research experience spans breast cancer, gynecologic oncology, and early-phase therapeutics, where careful monitoring is particularly important because experimental treatments may involve uncertain dosing, novel mechanisms, or previously unrecognized toxicities. She has also contributed to clinical trial awareness and outreach through the Carol Glock Foundation and has served NRG as a committee member, mentor, and liaison to the Breast Cancer Committee and Uterine Corpus Cancer Subcommittee.

Together, the appointments highlight how cancer research increasingly depends on collaboration across disciplines rather than on isolated discoveries. Biomarker scientists need reliable clinical samples and high-quality datasets; radiation and medical oncologists require pharmacy systems capable of delivering complex therapies; and clinical research teams need experienced mentors to sustain the workforce behind multicenter trials. NRG Oncology said the new leaders will help advance its research while continuing the contributions of outgoing vice chairs. Current committee leadership and member openings are listed on the organization’s website.

Subject of Research: Leadership changes in a major oncology clinical trials network, with emphasis on translational cancer research, biomarkers, pharmacy operations, clinical trial data management, and research mentorship.

Article Title: NRG Oncology Appoints New Leaders to Advance Precision Cancer Research and Clinical Trials

Web References: https://www.nrgoncology.org/Current-Openings ; https://www.nrgoncology.org

References: NRG Oncology leadership announcement and organizational information provided in the source material.

Keywords: NRG Oncology, cancer research, clinical trials, translational science, biomarkers, circulating tumor DNA, liquid biopsy, radiation oncology, gynecologic oncology, pharmacy research, RECIST, precision medicine, oncology leadership, clinical research mentorship

As chair, Welm inherits a multifaceted mandate to sculpt a visionary roadmap aligning research excellence with academic innovation, fostering a robust ecosystem that bridges laboratory discoveries with clinical applications. Her leadership will be instrumental in steering the department’s research priorities in synergy with University of Utah Health and Huntsman Cancer Institute, ensuring that cutting-edge scientific insights translate into tangible improvements in cancer diagnoses and therapies.

Balancing administrative stewardship with scientific oversight, Welm will spearhead efforts to secure competitive federal and private funding, emphasizing peer-reviewed grants, particularly from the National Institutes of Health. She will also oversee academic programming, faculty development, and resource allocation—pillars essential for sustaining a vibrant research culture that prioritizes both fundamental and translational oncology.

Welm’s expertise is deeply rooted in elucidating the complex mechanisms underlying breast cancer metastasis—a formidable challenge in oncology where understanding cellular dissemination and colonization is pivotal to innovating treatments. Her labs have successfully transitioned foundational discoveries into clinical hypotheses, illuminating pathways that govern tumor progression and therapeutic resistance.

Notably, Welm’s research employs sophisticated molecular biology techniques, coupled with advanced in vivo models, to dissect the signaling networks and tumor microenvironment interactions that fuel metastatic spread. This integrative approach underscores a commitment to unraveling cancer’s heterogeneity and pinpointing precise molecular vulnerabilities amenable to intervention.

Describing Welm’s appointment, interim dean Sam Finlayson, MD, highlights her unique capacity to fuse visionary science with collaborative leadership. This dual capability is essential in today’s intricate biomedical landscape, where interdisciplinary teams catalyze breakthroughs, and mentorship shapes future scientific leaders. Welm exemplifies this paradigm through her record of fostering translational initiatives and securing substantial external funding.

Welm’s academic journey traces a path through rigorous training and impactful scholarship. She obtained her PhD in cell and molecular biology at Baylor College of Medicine, completing advanced postdoctoral studies at the University of California, San Francisco. Since founding her laboratory at Huntsman Cancer Institute in 2007, she has consistently expanded its role as a nexus for pioneering breast cancer metastasis research.

Her ascension to chair is lauded by Mary Beckerle, PhD, CEO of Huntsman Cancer Institute, who emphasizes Welm’s international stature and exceptional ability to catalyze interdisciplinary collaborations spanning researchers, clinicians, and patient advocates. Such coalitions are vital in translating molecular insights into clinical innovations capable of improving patient outcomes globally.

Welm’s accolades attest to her scientific impact. In 2023, she received the University of Utah Distinguished Research Award and the American Association for Cancer Research Outstanding Investigator Award for Breast Cancer Research. Additionally, her presidency of the Metastasis Research Society underscores her leadership on the international stage, facilitating research aimed at understanding and interrupting metastatic disease processes.

Articulating her vision, Welm expresses a profound commitment to advancing a culture of scientific excellence and innovative collaboration within the department. She aims to harness the department’s strengths to train the next generation of cancer researchers and clinicians, positioning the University of Utah and Huntsman Cancer Institute at the forefront of emerging cancer therapies and precision medicine.

Welm’s leadership comes at a time when interdisciplinary and translational research is increasingly recognized as essential in oncology. By guiding the department’s academic and operational frameworks, she is poised to elevate its national profile and impact, ensuring that discoveries in molecular oncology swiftly inform clinical trials and patient care strategies.

Her predecessor, Brad Cairns, PhD, is credited with laying a robust foundation through recruiting high-impact investigators and fostering environments conducive to translational breakthroughs. Though stepping down as chair, Cairns remains a vital figure as a Howard Hughes Medical Investigator, continuing to influence cancer research and mentorship at the University of Utah and Huntsman Cancer Institute.

The Huntsman Cancer Institute itself, designated as a National Cancer Institute Comprehensive Cancer Center, serves a vast multi-state region with cutting-edge research and clinical trials focused on a cancer-free future. Its integration with University of Utah Health’s academic and clinical resources creates a synergistic hub for innovative cancer care and discovery.

With over 300 active clinical trials and more than 250 research teams, Huntsman Cancer Institute exemplifies the translational research model Welm aims to amplify. Its rich history of genetic discoveries and tailored cancer treatments provides a fertile context for Welm’s leadership to further scientific exploration into the molecular determinants of cancer metastasis and therapeutic resistance.

Located within a comprehensive academic health system, University of Utah Health boasts extensive biomedical research infrastructure and healthcare delivery networks, encompassing multiple hospitals and clinics. This environment offers Welm a powerful platform to align research priorities with patient-centered care, accelerating the bench-to-bedside trajectory of oncological innovations.

In sum, Alana Welm’s appointment as chair of the Department of Oncological Sciences heralds a transformative era for cancer research at the University of Utah. Her scientific acumen, strategic vision, and commitment to mentorship promise to advance molecular oncology, bolster translational research, and ultimately impact cancer treatment paradigms on a national and international scale.

—

Subject of Research: Breast cancer metastasis, translational oncology, molecular mechanisms of cancer progression
Article Title: Alana Welm, PhD, Named Chair of Oncological Sciences at University of Utah, Catalyzing Advances in Breast Cancer Metastasis Research
News Publication Date: Not explicitly provided; assumed current
Web References:
– https://medicine.utah.edu/faculty/alana-l-welm
– https://medicine.utah.edu/oncological-sciences
– https://healthcare.utah.edu/huntsmancancerinstitute/
References: Not explicitly cited in the original content
Image Credits: Emily Bade, Huntsman Cancer Institute
Keywords: Breast cancer, cancer metastasis, translational research, oncological sciences, Huntsman Cancer Institute, University of Utah

Dr. Hari’s arrival signifies a transformative step in the deployment of precision oncology in the region, as he brings a specialized expertise in nuclear oncology combined with translational science aimed at deciphering metabolic processes in cancer progression. Pennington Biomedical’s Executive Director, Dr. John Kirwan, emphasized that this addition reflects “a deep investment in the future of cancer research and patient-centered innovation,” positioning the center to compete for the esteemed National Cancer Institute (NCI) Cancer Center designation. This classification would elevate Louisiana’s status as a national leader in cancer research, leveraging Dr. Hari’s integrated clinical and laboratory research skills.

In his new role, Dr. Hari will spearhead a research program centered on nuclear medicine, an area that has seen remarkable breakthroughs through the discovery and development of theranostic agents. These agents—capable of both diagnostic imaging and targeted therapeutic delivery—offer unparalleled promise to millions of cancer patients by enhancing treatment specificity and efficacy. His research promises to deepen understanding of cancer metabolism pathways and facilitate the design of precision therapeutics that exploit metabolic vulnerabilities within tumors.

The field of nuclear oncology, where Dr. Hari’s expertise lies, is at the forefront of clinical innovation. It combines radiopharmaceuticals that deliver radioactive isotopes directly to cancer cells, enabling highly selective tumor imaging and destruction while sparing healthy tissue. This approach exemplifies the principles of precision medicine, targeting molecular and metabolic aberrations unique to individual patients’ tumors, which may revolutionize outcomes for various cancer types, including those traditionally resistant to conventional therapies.

Beyond the laboratory, Dr. Hari will dedicate a significant portion of his efforts to direct patient care through a clinical partnership with Mary Bird Perkins Cancer Center. This collaboration enhances the translational impact of his work, ensuring that laboratory discoveries rapidly inform clinical protocols and patient treatment strategies. Jodi Conachen, Chief Operating Officer at Mary Bird Perkins, recognized Dr. Hari’s leadership as integral to elevating oncology treatment standards, underscoring the importance of institutional collaboration in expanding access to cutting-edge cancer care.

As a member of the Louisiana Cancer Research Center (LCRC), Dr. Hari will integrate his nuclear medicine initiatives with ongoing statewide efforts to combat cancer’s burden. LCRC functions as a hub uniting over 200 researchers from universities and medical centers, including LSU Health New Orleans, Tulane University School of Medicine, Xavier University of Louisiana, and Ochsner Health, fostering interdisciplinary research that spans basic science to clinical applications. This network aims to accelerate cancer prevention research, early detection methods, and the transition of novel treatments into clinical settings.

His work will also support the LSU-led preparations for the forthcoming submission of the NCI Cancer Center Support Grant, a critical milestone in securing additional funding and resources to scale cancer research infrastructure in Louisiana. Collaborators such as Sven Davisson, LCRC’s Chief Administrative Officer, highlighted that Dr. Hari’s specialized knowledge in nuclear medicine will enhance the center’s research capabilities and clinical offerings, ultimately driving systemic improvements in cancer care across the state.

Dr. Hari’s academic and professional background is robust and multidisciplinary, positioning him well to impact precision oncology deeply. He received his medical degree from Kurnool Medical College, India, before pursuing doctoral studies in Clinical and Translational Science at Case Western Reserve University. Most notably, he completed a prestigious Nuclear Oncology Fellowship at Memorial Sloan Kettering Cancer Center, a global leader in cancer research and treatment. This fellowship equipped him with advanced training in radiopharmaceutical development, clinical trial execution, and molecular imaging techniques.

At Pennington Biomedical, known for its cutting-edge research into chronic diseases such as obesity, diabetes, cardiovascular disease, cancer, and dementia, Dr. Hari will join a vibrant ecosystem of over 600 research professionals engaged in clinical, population, and basic science investigations. The center’s infrastructure supports high-throughput technologies and state-of-the-art core facilities enabling interdisciplinary approaches to elucidate complex biological phenomena underpinning metabolic diseases and cancer.

Dr. Lucio Miele, Director of the LSU LCMC Health Cancer Center, articulated enthusiasm about Dr. Hari’s arrival, spotlighting the synergistic collaboration spanning multiple Louisiana institutions. This coalition embodies a model of cooperative science and clinical advancement, aiming to accelerate breakthroughs in cancer prevention, early detection, and therapeutics. In uniting research and clinical expertise across Pennington Biomedical, Mary Bird Perkins, LSU LCMC Health, LSU Health New Orleans, and the Louisiana Cancer Research Center, Louisiana is poised to make significant gains toward reducing cancer morbidity and mortality statewide.

The broader implications of Dr. Hari’s work in nuclear oncology and cancer metabolism cannot be overstated. With precision medicine increasingly becoming the standard of care, the integration of metabolic imaging and targeted radiotherapy holds promise for more personalized, less toxic, and more effective cancer treatments. As the therapeutic landscape evolves, innovations originating from Dr. Hari’s research may translate into improved survival rates and quality of life for patients, addressing cancers that have historically lacked effective targeted treatments.

Pennington Biomedical’s commitment to this initiative reflects a strategic vision to not only understand disease mechanisms at a cellular and systemic level but also to translate these discoveries into scalable health solutions. Dr. Hari’s expertise strengthens this ambition, bridging the gap between molecular science and patient-centered clinical application, and positioning the center as an epicenter for innovative cancer research and therapy development.

In summary, the recruitment of Dr. Adithya Hari represents a major milestone for Louisiana’s oncology research continuum. His cutting-edge expertise in nuclear oncology and metabolic science, coupled with robust institutional collaborations, sets the stage for transformational advancements in cancer diagnosis, management, and prevention. This integrated approach underlines the promise of precision medicine to tackle one of the world’s deadliest diseases with unprecedented focus and innovation.

Subject of Research: Cancer Metabolism, Nuclear Medicine, Precision Oncology

Article Title: Pennington Biomedical Welcomes Dr. Adithya Hari to Advance Cancer Metabolism and Nuclear Oncology Research

News Publication Date: April 21, 2024

Web References:

• Pennington Biomedical Research Center: http://www.pbrc.edu
• Mary Bird Perkins Cancer Center: https://marybird.org/
• Louisiana Cancer Research Center: https://www.louisianacancercenter.org/
• LSU LCMC Health Cancer Center: https://www.medschool.lsuhsc.edu/cancer_center/

Image Credits: Madison Page, PBRC

Keywords: Cancer, Oncology, Cancer Risk, Cancer Genetics, Cancer Metabolomics, Cancer Screening, Cancer Patients, Tumor Growth, Tumor Regression, Medical Research Facilities, Educational Facilities, Laboratories, Scientific Facilities, Education, Universities, Educational Institutions

The research indicates that blocking MARCO alters the behavior of immune cells within the tumor microenvironment. This alteration results in an increased influx of immune cells, which subsequently augments the effectiveness of anti-CTLA4 treatments. This development is particularly significant for what are termed "cold" tumors—cancers that typically lack sufficient immune cell presence and often prove resistant to conventional immunotherapies. The findings suggest that targeting MARCO can help mobilize the immune system in a way that was previously unattainable for many patients suffering from these challenging tumor types.

James Mulé, who serves as the associate center director for Translational Science at Moffitt and leads the study, articulated the research’s implications by noting that targeting MARCO could bolster the efficacy of existing immunotherapeutic drugs without necessitating the depletion of macrophages. This finding not only introduces a new paradigm for treating melanoma but also lays the groundwork for broader application in various types of cancers, providing hope to those in need of innovative treatment options.

Investigators performed an experimental study utilizing animal models, wherein they introduced a monoclonal antibody aimed at MARCO, observing its effects when combined with anti-CTLA4 therapy. The results were striking: the combination treatment led to a substantial increase in immune cell infiltration within the tumor. Dendritic cells, which are instrumental in priming the immune response against tumors, showed particular enhancement in their numbers following the combination therapy, highlighting the synergistic potential of this new approach.

It is intriguing to note that this study specifically mentioned that similar improvements were not observed when anti-MARCO therapy was paired with anti-PD1 treatment. This distinction underscores the unique role MARCO plays in enhancing anti-CTLA4 efficacy. The researchers emphasize the necessity of further dissecting the underlying mechanisms at play to better understand the immunological dynamics following MARCO inhibition.

Furthermore, the study opens doors for clinical trials aimed at integrating MARCO-targeting strategies into both neoadjuvant and adjuvant therapy settings. By mitigating the chances of cancer recurrence through enhanced immune preparation within the tumor microenvironment, the findings could significantly reshape our approach to cancer prevention and treatment.

Publications such as these have essential implications not only for melanoma treatment but also for a multiplicity of cancers where current therapies fall short. This research underlines the importance of continual innovation in cancer treatment modalities, striving to provide more comprehensive care to patients.

The significance of this study cannot be overstated, as it brings to light the intricate interplay between immune cells and tumor cells and emphasizes the need for tailored therapies that resonate with the biology of the disease. As Moffitt Cancer Center continues to push the envelope in cancer research, this study represents a vital stepping stone toward more effective and personalized treatment options for patients battling cancer.

In conclusion, the targeting of MARCO presents a promising avenue for enhancing the efficacy of immunotherapy for melanoma and potentially other cancers. The implications of this research are profound, suggesting that a redefined approach to immuno-oncology could lead to substantial improvements in patient outcomes. These findings herald an exciting future in cancer therapy, where personalized medicine and innovative strategies converge for better patient care.

Subject of Research: Animals
Article Title: Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming
News Publication Date: March 13, 2025
Web References: Moffitt Cancer Center
References: Journal for ImmunoTherapy of Cancer
Image Credits: None provided
Keywords: Immunotherapy, melanoma, MARCO, anti-CTLA4, cancer research, immune cells, tumor microenvironment, clinical trials, personalized medicine.